menu
    • menu
    [{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Made Scientific","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Partnership","leadProduct":"HG-CT-1","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Hemogenyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"HEMO-CAR-T","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"MD Anderson Cancer Center University of Texas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ MD Anderson Cancer Center University of Texas","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ MD Anderson Cancer Center University of Texas"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail Partners","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail Partners"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ KBI Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ KBI Biopharma"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Prevail InfoWorks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hemogenyx Pharmaceuticals \/ Prevail InfoWorks","highestDevelopmentStatusID":"6","companyTruncated":"Hemogenyx Pharmaceuticals \/ Prevail InfoWorks"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Discovery","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Hemogenyx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hemogenyx Pharmaceuticals \/ Hemogenyx Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Hemogenyx Pharmaceuticals

    Menu

    Hemogenyx Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Made Scientific

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Made Scientific and Hemogenyx Announce Technology Transfer and Manufacturing Partnership

                            Details : The partnership aims to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 08, 2025

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Made Scientific

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Hemogenyx raises £570,000 and Director's Dealing

                            Details : The net proceeds will be used for Phase I clinical trial of the Company's Chimeric Antigen Receptor T-cell therapy, HG-CT-1, aimed at treating relapsed/refractory acute myeloid leukemia.

                            Product Name : HG-CT-1

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            August 26, 2025

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HG-CT-1,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

                            Details : HG-CT-1 is a proprietary anti-FLT3 CAR-T cell therapy, being investigated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : HG-CT-1,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces First-in-Human Treatment with HG-CT-1

                            Details : HG-CT-1, is a CAR-T cell therapy, which is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : HG-CT-1

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : MD Anderson Cancer Center University of Texas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/refractory AML

                            Details : This drug candidate is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 22, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : MD Anderson Cancer Center University of Texas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HEMO-CAR-T

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial

                            Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated for the treatment of r/r acute myeloid leukemia.

                            Product Name : HEMO-CAR-T

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 22, 2024

                            Lead Product(s) : HEMO-CAR-T

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Prevail Partners

                            Deal Size : $0.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC

                            Details : THe proceeds will be used in clinical services and technologies for the Company's upcoming Phase I of an anti-FLT3 CAR-T cells in pediatric subjects with R/R AML and a subset of ALL.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Prevail Partners

                            Deal Size : $0.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HEMO-CAR-T

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces CDX Development Update

                            Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanized monoclonal antibody. It is being evaluated in preclinical studies for the treatment of r/r acute myeloid leukemia.

                            Product Name : HEMO-CAR-T

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 02, 2024

                            Lead Product(s) : HEMO-CAR-T

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HEMO-CAR-T

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold

                            Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated in preclinical studies for the treatment of acute myeloid leukemia.

                            Product Name : HEMO-CAR-T

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : HEMO-CAR-T

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Hemogenyx Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of Cancer

                            Details : Human macrophages, a type of immune cells, programmed with a purpose designed CBR, were able to eliminate Non-Hodgkin Lymphoma derived cells with high efficiency in vitro.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 27, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth